ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Feb 27, 2026, 18:30Sanjeev Saksena: From Isolated Case Reports to Clinical Evidence for Post-Ablation Myocardial Ischemia
-
Feb 27, 2026, 18:21Priya Prasad: Can Money Buy Blood?
-
Feb 27, 2026, 18:19Trulee Cardona: Hemophilia Care in Uzbekistan and Why It Matters
-
Feb 27, 2026, 18:19Bartosz Hudzik: Do Elevated Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Otherwise Healthy Women?
-
Feb 27, 2026, 18:14Mohamed Sikkander Abdul Razak: Factor XIa Inhibitors Show Promise With Lower Bleeding Risk
-
Feb 27, 2026, 18:09Hariom Rajput: Early Recognition and Prevention of Deep Vein Thrombosis
-
Feb 27, 2026, 18:08Karen Fahey: What If the Blood Products You Rely On Weren’t Safe?
-
Feb 27, 2026, 17:46Perla Bandini: Whole-Exome Sequencing Unveils Suspected Primary Hemostasis Disorders
-
Feb 27, 2026, 17:44Ekaterina Balaian: Exploring Fostamatinib Use in APS Patients with Thrombocytopenia